Clinical Program BL8040

BioLineRx’s BKT-140/BL-8040 Receives Orphan Drug Designation for Treatment of AML

BioLineRx’s BKT-140/BL-8040 Receives Orphan Drug Designation for Treatment of AML

September 9th, 2013|Clinical Program BL8040|

BioLineRx Announces Issuance of United States Patent

BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 for Obtaining Stem Cells

September 3rd, 2013|Clinical Program BL8040|

BioLineRx Reports Second Quarter 2013 Results

August 6th, 2013|Clinical Program BL8040|

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BKT-140/BL-8040, for Treatment of Leukemia

Partial results expected in Q4 2013.

June 6th, 2013|Clinical Program BL8040|

BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting

BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting

November 7th, 2012|Clinical Program BL8040|

BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers

September 4th, 2012|Clinical Program BL8040|